# A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

> **NCT02272777** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 225 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT02272777
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-17
- **Primary completion:** 2017-01-30
- **Final completion:** 2017-01-30
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02272777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02272777, "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02272777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*